Quiet Understanding

Here we gather together, despite the deafening silence, we can still attempt to make some sense of what we have.

Occasionally, we receive Pillars of Understanding in the form of PRs. From those, we create our own deductions going forward. And patterns emerge.

We've said several times, Lalezari is several steps ahead. In recent PRs, the discussions pointed to mTNBC and more recently, MSS mCRC. Max Lataillade hasn't yet spoken a word about CytoDyn's HIV progress, yet he sits at the Head of HIV Drug Development at the GF while simultaneously sitting as SVP of Clinical Development at CytoDyn, and still, not a peep about leronlimab being used in HIV. He did however, last week congratulate somebody at G for Yeztugo's approval.

Now, last week, I wrote Persistent Pressure With The Cure In Sight and even much more recently, Agreement In The Making, where both posts were totally about HIV. In both posts, I stressed that the time is soon approaching. The long acting leronlimab project, due at the end of the month on June 30, 2025 shall soon be resulted and I mentioned what should be some of the findings:

The Development of a Self-Administered At Home Formulation that would greatly increase patient compliance and adherence*.*

The formulation shall be one of low-Volume*, such that only a* small amount is necessary to be subcutaneously injected. Remember, CytoDyn's 3rd party AI Developing Partner is working with Scott Hansen, PhD and Jonah Sacha, PhD in the development of long-acting leronlimab.

The Optimal Clinical Dosing for long acting leronlimab shall be determined for HIV-Prep*, but this knowledge shall be extractable for other diseases as well. Diseases for which Scott Hansen, PhD expands the development of long acting leronlimab as treatment.*

The capacity for long acting leronlimab to prevent the transmission of HIV and to be functional and operable within the mucosa for a long acting period of time shall be determined.

One of the most difficult areas of the body to treat are the mucous membranes, as the blood supply to these areas is reduced and diminished. The purpose of the mucous membranes is to catch invaders, bacteria, viruses, fungus, mold, mildew before they enter the blood stream. But sometimes, some of these invaders actually infect these mucous membranes, instead of getting caught and trapped by them, and then, the body has great difficulty in the eradication of these microbial, fungal and viral infections because the medications including anti-biotics cannot reach these membranes due to the reduced blood supply. Therefore, the infection festers within the mucous membrane and slowly leaks out the infection to the blood supply to subsequently infect the body.

But, if long acting leronlimab has the capacity to reach the mucous membranes and remain there for 3+ months with a single subcutaneous injection, then, CytoDyn has something amazing which could have implications in any mucosal borne infection, even the very difficult to treat, rhinosinusitis."

I looked back and saw something similar. I extracted the following quote out of The Early Line HIV Connection

"That is 3 bombshells in a week or two all which concern long-acting HIV or Early Line HIV*. Isn't that saying something? Can it be denied that although the* majority of recent goals and objectives have not really mentioned HIV*, aside from* LATCH, that these 3 things almost act like sign posts that point to an HIV revival at least in its prevention or early eradication? Leronlimab crosses the Placenta; the addition of leronlimab to ART and bNAbs leads to the prevention of HIV reservoir development; Lastly, the hiring of Max Lataillade who served as VP Global Research Strategy at ViiV Healthcare. It is coming, like the others are coming; It is on the horizon. Now CytoDyn has two doctors in leadership with a deep seated ambition to overcome HIV. This natural progression tells me that something pertaining to LATCH may be uncovered soon.**"

Latching and expounding, In Laying Low, I said:

"CytoDyn wants each and every avenue here to work out just as they hope it should. Given that CytoDyn is not really running all things, CytoDyn is therefore dependent upon the proper execution of their trials to be successful. Take amfAR in LATCH and the Investigators in Berlin, Germany for examples. CytoDyn has high expectations because they were originally successful prior and now they want to repeat what they have already accomplished. So, therefore, we can have some hope and some trust that what they plan to do is all well and good, but can we guarantee it? Unfortunately not, but fortunately, CytoDyn shall have Max Lataillade, DO on the scene overseeing and ensuring the studies proceed according to protocol."

Declaring precisely what CytoDyn said about LATCH:

"As previously announced, CytoDyn will be partnering with the American Foundation for AIDS Research (amfAR) to sponsor the HIV LATCH study which will use leronlimab to protect CCR5+ donor immune cells from HIV infection while aiming for a cure in the setting of bone marrow transplantation provided to an HIV+ recipient*. It is the Company’s belief that the likelihood of success of the LATCH program was greatly enhanced with the recent announcement by investigators in Germany of* a successful HIV cure using stem cells from a donor who was heterozygous for the CCR5 delta-32 mutation*. Indeed, those same investigators have reached out to CytoDyn and asked if they too can run a similar LATCH program at their research center in Berlin, and we are currently taking steps to make this opportunity a reality."*

Reiterating Dr. Lalezari's Description of LATCH from the 5/30/24 Webcast:

"Dr. Lalezari 16:29: LATCH, Stem Cell Transplant HIV Cure

In addition to these two core clinical studies, I'm pleased to announce two other exciting clinical initiatives. First, we are in discussion with the American foundation for AIDS research to partner and co-sponsor a study called LATCH, led by investigators at Oregon Health Sciences University and the University of Washington, LATCH stands for Leronlimab and Allogeneic stem cell Transplant to Cure HIV*.*

The proposed study will evaluate the use of leronlimab to facilitate an HIV Cure in the HIV positive subjects, undergoing stem cell transplantation. Previous reports of HIV Positive patients achieving a cure have occurred when those RARE homozygous CCR5, double negative individuals have been identified to provide donor stem cells for the transplantation.

This study will evaluate the possibility that leronlimab could extend the list of potential donors to include the much larger pool of CCR5 positive individuals. Leronlimab would be administered following transplantation for six months during the engraftment period, to protect the HIV negative, donor cells from becoming HIV infected. The hope is that those donor cells now protected from HIV infection, will then eliminate HIV from the reservoir of the transplant recipient. If successful, this study would obviously bring about much needed positive attention to both leronlimab and CytoDyn. We're exploring this partnership with AMFAR to jointly co-sponsor and fund the research aspects of the LATCH study, which importantly, will not require us to cover the cost of the transplant itself*."*

Dr. Lalezari mentioned 6 months. I'm sure Scott Hansen has a 6 month version of long acting leronlimab. My thoughts are that AMFAR would prefer to use 6-month long acting leronlimab version of the 17 for their LATCH trials. They would administer it only once instead of weekly for 6 months. LATCH may have been held up waiting for the long lasting leronlimab NIH Project to END on 6/30/25. But, they could also have used the weekly version as well, but I see LATCH as an ideal candidate for long acting leronlimab. Can Yeztugo be used in LATCH? Of course not. It can not be used in HIV+ patients. Remember, even if you flush out the Bone Marrow and Stem Cells from an HIV+ patient, the Reservoir still remains which is HIV+. For it to be successful, it requires leronlimab administered for 6 months to protect, the non-infected CCR5+ T-Cells to eradicate the HIV+ Reservoir. After 6 months, the entire Reservoir is gone and the patient is CURED. LATCH in a nut-shell.

In addition, all of the results from the Project Ending 6/30/25 puts long acting leronlimab ahead of Yeztugo. Yeztugo is only indicated for HIV negative patients. It can not be used in HIV+ patients, so count LATCH out for Yeztugo. Leronlimab can be used in either HIV- or + patients. Yeztugo is physician administered at the doctor's office while leronlimab is patient administered. Yeztugo is only indicated for HIV PrEP and not for any other HIV indications, while leronlimab may be indicated for an entire spectrum of problems ranging from HIV+, HIV PrEP, Cancer, Inflammation and Infection. Leronlimab enters the mucous membranes and dwells there, attached to the CCR5 receptors for months on end, until its half-life is reached at which point another leronlimab subcutaneous injection should be administered. While active, there in the mucous membrane, it performs its functions. Yeztugo doesn't function in the mucous membranes.

Much of what I just said, shall be said again when the results of this June Ending Project are released. So then, what does this all mean? I see it as a turning point which transforms CytoDyn shareholder's fear into hope and paves the way towards an Agreement, a Partnership involving long acting leronlimab in some HIV indication.

I see it as a reversal of what G is trying to achieve. First off, they develop a drug that prevents the transmission of HIV from one person to another, so that HIV may not be transmitted, however, they make it exorbitantly expensive. Paying for the drug seems like its going to be an issue which limits accessibility to the drug. It appears as if its going to be more of a burden to pay for it, than to seek another sort of protection. So then, why did they develop the drug? To make it so expensive that nobody actually uses it? Do they really want to stop the spread of HIV or are they just selling a story?

CytoDyn has a better answer. Who knows, long acting leronlimab could exceed the original 3 month half life goal which they were originally shooting for. Maybe it works for 4 months. Maybe it works for 6 months. Maybe even a year? Max mentioned a year. Regardless, CytoDyn fights back and the results don't lie. Coming soon: the hunted becomes the hunter.

Any one of these long acting leronlimab formulations may be utilized in the LATCH pilot trials, preferably the 6 month long acting version, coming in 2025. "The LATCH protocol is scheduled to complete final updates at the end of December, and we look forward to the launch of this program in 2025."

To add to that, by the end of 2025, an answer for the HIV Reservoir shall be known. The combination of that with the results of the long acting leronlimab project, combined also with the results of bNAbs, HAART, along with the results of leronlimab-PLS shall result in an Agreement; in a Partnership and in multiple products which prevent the transmission of HIV in HIV+ and HIV- patients. They shall also be used to completely eradicate HIV from HIV+ patients using the LATCH Technique and because knowledge and understanding of the Reservoir shall be complete.

When shall the disclosure of this partnership be announced? Knowing everything I've laid out, I would think it would be quite soon. Who do I think it is with? GF, GSK and ViiV. How do I think the announcement is made? Cash Infusion. When again? With a timing which is hard to ignore.

I think the moment now is upon the world where it can no longer be ignored what is being discovered about our molecule and the various long acting molecules. Though he was silent as a lamb, history is about to hear Lion Lalezari's Roar through his coming Press Released statements. Just as he said he would in the past, he has positioned CytoDyn perfectly for what just lies ahead.

Many are in support of Sacha's work, including much of the world. That HIV Cure is coming, and sooner than many might think. Everything is on schedule and according to plan.

You don't think G is worried? OK. Boy, they are so assured about their new Yeztugo. You think? OK. Sure. Even our own Max praised them. Come on, you know how that game is played. Get real, why don't you?

They're scared shitless. What's coming is not good news at all for them. CytoDyn becomes even a greater burden for them. One blow after another, which can not be stopped, because of the support of the results that greatly help the people on Planet Earth. Who backs these people? Yes, the GF. Bill Gates. GSK and ViiV and what they develop from the findings of all these Projects and LATCH pilot trials obliterates the traditional methods in which HIV is currently treated from that day forward.

The Potential Energy is building up to a coming event at which point it is transformed to Kinetic Energy. Signs point to the proximal future when CytoDyn becomes a force to be reckoned with.

Not sure how G deals with what's coming. Assuredly, they are already upset with CytoDyn that all these projects are in development for HIV-PrEP, long acting leronlimab, LATCH, The Reservoir, and HIV-AAV Functional Cure. Notice something, I didn't say anything about Cancer even though it is also in development. I mentioned only the HIV indications because G is a great burden to CytoDyn in HIV indications, and less so in Cancer, but not by much. So I do expect an up rise out of them and in that specific up rise, I expect that G is taken out, just like when Haman & sons were hung in their very own gallows.